Get the Stockscreener App
3.27
2.39%
-0.08
After Hours:
3.28
0.010
+0.31%
Lisata Therapeutics Inc stock is traded at $3.27, with a volume of 31,522.
It is down -2.39% in the last 24 hours and down -2.39% over the past month.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.
See More
Previous Close:
$3.35
Open:
$3.32
24h Volume:
31,522
Relative Volume:
0.33
Market Cap:
$29.78M
Revenue:
$170.00K
Net Income/Loss:
$-16.35M
P/E Ratio:
-1.7576
EPS:
-1.8605
Net Cash Flow:
$-13.66M
1W Performance:
-3.82%
1M Performance:
-2.39%
6M Performance:
+54.98%
1Y Performance:
+31.85%
1-Day Range:
$3.26
$3.33
1-Week Range:
$3.26
$3.44
52-Week Range:
$1.81
$5.07
Lisata Therapeutics Inc Stock (LSTA) Company Profile
Name
Lisata Therapeutics Inc
Sector
Industry
Phone
908-229-2590
Address
110 ALLEN ROAD, BASKING RIDGE
Compare LSTA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LSTA
Lisata Therapeutics Inc
|
3.27 | 30.51M | 170.00K | -16.35M | -13.66M | -1.8605 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lisata Therapeutics Inc Stock (LSTA) Latest News
Lisata Therapeutics, Inc. Actuals & Estimates (DUS:8NE) - TradingView
LSTA Forecast — Price Target — Prediction for 2027 - TradingView
Johnson Fistel Investigates Lisata Therapeutics, Inc. (LSTA) After Disclosures Concerning Acquisition Financing - GlobeNewswire
Lisata Therapeutics, Inc. Actuals & Estimates (NASDAQ:LSTA) - TradingView
Lisata Therapeutics Inc (LSTA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Lisata Therapeutics Inc (LSTA) Institutional Confidence - TradingKey
Lisata Therapeutics Inc (LSTA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Lisata Therapeutics Inc (LSTA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Lisata Therapeutics Inc (LSTA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Lisata Therapeutics Inc (LSTA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Lisata Therapeutics Inc (LSTA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Lisata Therapeutics Inc (LSTA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Lisata Therapeutics Inc (LSTA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Lisata Therapeutics, Inc. (LSTA) - marketscreener.com
Lisata Therapeutics (LSTA) Rises 2.3% as Stock Tests Key ResistanceHigh Conviction Picks - newsline.com
LSTA Rallies 2.3% to $3.56 as Support Holds Ahead of ResistanceDip Buy Trade - newsline.com
LSTA Q3 2025 Earnings: EPS Beat Exceeds Expectations as Clinical Progress ContinuesQuarterly Financial Update - newsline.com
Lisata shares nearly double on buyout offer: Here are the details - MSN
Kuva Labs Agrees to Acquire Lisata Therapeutics for Four Dollars Per Share - HarianBasis.co
Lisata Therapeutics agrees to Kuva Labs buyout at $4 per share - Yahoo Finance
Kuva Labs launches $4/share tender offer to acquire Lisata Therapeutics, plus potential $3/share milestone payments. - Pluang
Lisata Therapeutics (NASDAQ: LSTA) to be acquired for $4.00 cash plus CVRs - Stock Titan
Kuva Labs subsidiary offers $4.00 plus CVR to acquire Lisata (LSTA) - Stock Titan
Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc. - GlobeNewswire
LSTA SEC FilingsLisata Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
LSTA Q3 2025 Earnings: Narrower Loss Surpasses Estimates as Clinical Progress ContinuesCFO Commentary Report - newsline.com
Lisata Therapeutics, Inc. Announces Amendment and Waiver to Merger Agreement with Kuva Labs Inc. and Kuva Acquisition Corp – Minichart - Minichart
Lisata Therapeutics Amends Kuva Labs Merger Agreement Timeline - TipRanks
Lisata Extends Kuva Labs Merger Timeline; Outside Date to July 17, $1.5 Million Option to Aug 17 - TradingView
Lisata Therapeutics (LSTA) extends Kuva Labs tender offer deadlines and adds $1.5M extension fee - Stock Titan
LSTA Q3 2025 Earnings: EPS Surpasses Estimates Despite Lack of Revenue, Stock Edges LowerRetail Earnings Report - newsline.com
LSTA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Lisata Therapeutics (LSTA) Holds Steady at $3.37 as Key Levels NarrowPCR Spike - newsline.com
Lisata Therapeutics (LSTA) Eases Amid Modest Pullback — Key Support Levels in FocusMoving Average Crossovers - newsline.com
LSTA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Lisata Therapeutics agrees to $5 per share acquisition by Kuva Labs - Investing.com
Lisata Therapeutics Faces Uncertainty in Kuva Tender Offer - The Globe and Mail
Lisata Therapeutics (LSTA) Files 8-K on Proposed Acquisition and Tender Offer – Key Information for NASDAQ Investors - Minichart
Kuva to seek Lisata tender offer (LSTA) under March 6, 2026 merger - Stock Titan
Lisata Therapeutics merger tender offer delayed as Kuva Labs reviews financing - Investing.com UK
Tender offer for Lisata Therapeutics (LSTA) delayed as Kuva Labs reevaluates timing - Stock Titan
Lisata Therapeutics Announces Amendment to Merger Agreement with Kuva Labs and Contingent Value Rights Agreement - Minichart
LSTA Q3 2025 Earnings: Narrower-Than-Expected Loss Marks Progress in Clinical-Stage BiotechRevenue Growth Outlook - The Legal Advocate
What are the Core Details of the Kuva Labs Acquisition of Lisata Therapeutics - Kavout
Stocks to Watch: Oculis, Lisata, Healthy Choice Wellness - Moomoo
Lisata Therapeutics Revises Merger Terms, Adds Milestone CVRs - TipRanks
Lisata Therapeutics (LSTA) preliminary tender-offer communication; merger dated March 6, 2026 - Stock Titan
Lisata Therapeuticsamends merger offer price to $4 per share plus CVR - marketscreener.com
Lisata Agrees to $4 Cash Plus Up to $3 CVR in Amended Kuva Tender Offer - TradingView
Lisata (NASDAQ: LSTA) cuts cash to $4, lifts CVR upside to $3 - Stock Titan
LSTALisata Therapeutics Inc Stock Price and Quote - Finviz
Lisata Therapeutics Inc Stock (LSTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.17%
2.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):